CJC-1295
Long-acting GHRH analogue with Drug Affinity Complex
CJC-1295 is a long-acting GHRH analogue containing a Drug Affinity Complex designed to bind circulating albumin and prolong exposure. Early human studies evaluated pharmacokinetics, pulsatile GH secretion and circulating IGF-1 rather than clinical performance or longevity outcomes.[1]
01 / Overview
Quick facts
Somente campos atualmente documentados aparecem neste registro.
- class
- GHRH analogue with DAC
- molecule Type
- Modified peptide analogue
- primary Target
- Pituitary somatotroph
- receptor
- GHRHR
- primary Axis
- GH / IGF-1
- half Life
- 5.8–8.1 days (human study estimate)
- research Status
- Investigational
- developer
- ConjuChem
- first Described
- 2005
What is it studied for?
Dose-dependent and sustained endocrine biomarker changes were studied in healthy adults.
Receptor activation, albumin association and growth effects were investigated in rat and GHRH-knockout mouse models.
A small human study explored serum protein changes following GH/IGF-1-axis activation.
02 / Mechanism
Mechanism of action
Fluxo estruturado para navegação. Uma seta indica sequência conceitual, não necessariamente interação direta.
03 / Evidence synthesis
What does the evidence actually show?
As categorias evitam misturar evidência humana, dados pré-clínicos e plausibilidade mecanística. A cobertura desta versão não é uma revisão sistemática.
Data not indexed yet.
- Human pharmacokinetic and pharmacodynamic effects on GH and IGF-1 are documented.
- The human evidence base is small and centered on biomarkers and short-term exposure.
- Receptor pharmacology and growth-model findings support biological activity but are not clinical outcomes.
- GHRHR–Gs–cAMP signaling and DAC-mediated albumin association explain the observed prolonged exposure.
- Muscle gain, fat loss, athletic recovery, anti-aging and longevity benefits are not established by the indexed CJC-1295 studies.
- Evidence for CJC-1295 with DAC must not be transferred to products labelled CJC-1295 without DAC or Modified GRF (1–29).
Published evidence
What does the evidence actually show?
- Human
- 3
- Animal
- 2
- In vitro
- 0
- Ex vivo
- 0
- Reviews
- 0
CJC-1295 produced sustained, dose-dependent increases in circulating GH and IGF-1 in early healthy-adult studies. [1]
- Early-phase studies
- Biomarker outcomes rather than clinical benefit
GH secretion remained pulsatile during continuous pharmacological exposure in the indexed human analysis. [2]
Daily administration increased growth in a GHRH-knockout mouse model; this does not establish a human growth indication. [4]
The DAC strategy extended exposure through albumin association while retaining GHRHR agonism in preclinical characterization. [5]
04 / Published protocols
Dosing reported in published human studies
The values reproduce protocols described in published research. They are not recommendations, prescriptions or clinical guidance.
| Study | Population | N | Route | Dose reported | Frequency | Duration | Design | Primary outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Sam L. Teichman et al. | Healthy adults aged 21–61 years | Not reported in the consulted source | Subcutaneous | Ascending single doses and weekly or biweekly multiple doses; the abstract identifies 30 or 60 µg/kg as particularly well tolerated | Single administration; weekly or biweekly in the multiple-dose trial | 28 and 49 days | human-rct · not-extracted | Peak concentration and area under the curve of GH and IGF-1; CJC-1295 pharmacokinetics | Open |
| M. Ionescu et al. | Healthy adults from the CJC-1295 pharmacology program | Not reported in the consulted source | Subcutaneous | — | — | — | human-clinical · needs-review | GH pulse frequency and amplitude during prolonged CJC-1295 exposure | Open |
| L. Sackmann-Sala et al. | Healthy adults exposed to CJC-1295 | Not reported in the consulted source | — | — | — | — | human-clinical · needs-review | Serum protein profile changes associated with GH/IGF-1-axis activation | Open |
Experimental protocols
Experimental protocols
In vitro concentrations, ex vivo conditions and animal doses are experimental protocols and are not equivalent to human doses.
| Study | Population | N | Route | Dose reported | Frequency | Duration | Design | Primary outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|
| M. Alba et al. | GHRH-knockout mice | Not reported in the consulted source | — | — | Once daily | — | animal · needs-review | Body growth; GH/IGF-axis markers | Open |
| L. Jetté et al. | Anterior-pituitary receptor assays and rat pharmacology | Not reported in the consulted source | — | — | — | — | animal · needs-review | GHRHR activation; Albumin association; Duration of pharmacological activity | Open |
05 / Pharmacokinetics
Pharmacokinetics
- Half-life
- 5.8–8.1 days (estimated in the early human studies)
- Route studied
- Subcutaneous
- Measurable pharmacodynamic activity
- Mean GH remained elevated for at least 6 days and IGF-1 for 9–11 days after a single administration
- Binding characteristic
- DAC-mediated association with albumin
06 / Safety
Safety & Adverse Events
Reported findings
- No serious adverse reactions were reported in the early human pharmacology report.
Pharmacological concerns
- Sustained stimulation of the GH/IGF-1 axis has pharmacological implications that cannot be characterized from small, short studies alone.
Unknowns
- Long-term safety, uncommon harms and clinical outcomes remain insufficiently characterized.
- The indexed studies do not establish safety for unsupervised or non-research use.
07 / Source literature
Studies
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Journal of Clinical Endocrinology & Metabolism · Sam L. Teichman et al.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Journal of Clinical Endocrinology & Metabolism · M. Ionescu et al.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Growth Hormone & IGF Research · L. Sackmann-Sala et al.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
American Journal of Physiology-Endocrinology and Metabolism · M. Alba et al.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Endocrinology · L. Jetté et al.
Multiple entry points
Related Paths
CJC-1295 can also be explored through these curated graph routes.
No dead ends
Continue Exploring
GHRHR
target
GHRHR is a class b g protein-coupled receptor connected to Gs, Adenylyl cyclase, cAMP, PKA, GH release.
DAC-mediated Albumin Association
pathway
Estratégia de extensão de exposição em que o grupo Drug Affinity Complex do CJC-1295 se associa à albumina circulante; albumina atua como carreador, não como receptor farmacológico.
Growth Hormone
topic
Hormônio peptídico pituitário integrado ao eixo somatotrófico.
IGF-1
topic
Fator de crescimento que atua por IGF1R e participa de múltiplos processos de crescimento e metabolismo.
GH / IGF-1 Axis
pathway
Eixo endócrino que conecta sinalização hipotalâmica e pituitária à produção e ação de IGF-1.
GHRH Signaling
pathway
Ativação de GHRHR em somatotrofos com sinalização Gs, adenilil ciclase, cAMP e PKA.
cAMP Signaling
pathway
Rede de segundo mensageiro gerada por adenilil ciclase e interpretada por efetores como PKA e EPAC.
Pituitary
tissue
Endocrine gland containing hormone-secreting cell populations including somatotrophs.
Index coverage
Literature coverage
Search updated 2026-09-02 · 5 included · 28 excluded after screening
Search strategy
PubMed
CJC-1295CJC 1295CJC1295CJC-1295 AND growth hormoneCJC-1295 AND IGF-1
Inclusion criteria
- CJC-1295 was the direct pharmacological, mechanistic or analytical subject
- Primary biological studies and directly informative human analyses
Exclusion criteria
- Incidental mentions
- Doping-detection methods
- Market-use reports
- General reviews without compound-specific data
- CJC-1295 without DAC terminology
09 / References
References
- [1]
Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006.
- [2]
M. Ionescu, L. A. Frohman. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006.
- [3]
L. Sackmann-Sala, J. Ding, L. A. Frohman, J. J. Kopchick. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009.
- [4]
M. Alba, D. Fintini, A. Sagazio, B. Lawrence, J. P. Castaigne, L. A. Frohman, R. Salvatori. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
- [5]
L. Jetté, R. Léger, K. Thibaudeau, C. Benquet, M. Robitaille, I. Pellerin, V. Paradis, P. van Wyk, K. Pham, D. P. Bridon. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005.